RxDoctor Payments Data

Christopher Parlee, MD

Family Medicine · Fort Worth, TXNPI 1619471315

Payments from drug & device makers

$6,003in general payments, 2019–2025

Across 354 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$905
  • Lilly USA, LLC$832
  • AstraZeneca$557
  • Novo Nordisk$541
  • Exact Sciences$396
  • Pfizer$309
  • plus $2K from 41 others

What the payments were for

  • Food & beverage$6,003100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,003 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$3,958
Medicare patients
21
Services billed
136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin70$96,955
OzempicSemaglutide18$27,331
RybelsusSemaglutide12$22,356
MounjaroTirzepatide20$21,689
JanuviaSitagliptin Phosphate15$19,229
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$8,415
Duloxetine Hcl41$1,610
Rosuvastatin Calcium190$1,496
Atorvastatin Calcium189$1,200
Metformin Hcl ErMetformin Hcl102$824
Bupropion XlBupropion Hcl19$780
Lisinopril104$740
Levothyroxine Sodium82$699
Albuterol Sulfate HfaAlbuterol Sulfate24$694
Gabapentin31$667

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$245$96,95570 claims
Novo NordiskOzempic, Rybelsus$541$49,68730 claims
Lilly USA, LLCMounjaro$832$21,68920 claims
MerckJanuvia$113$19,22915 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$74$69982 claims
AbbVieSynthroid$905$21011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →